Kinnate Biopharma Q2 EPS $(0.62) Down From $(0.49) YoY

Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) per share from the same period last year.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) per share from the same period last year.

Apple App Store Settlement Reveals Updates: How Did A BofA Analyst React?

By Priya Nigam

August 27, 11:30 AM

Although Apple Inc.’s (NASDAQ: AAPL) App Store changes are still pending court approval, they will resolve a class-action suit from U.S. developers, according to BofA Securities.

AAPL

53 Biggest Movers From Yesterday

By Lisa Levin

April 8, 4:49 AM

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.

ADN

RPM Sees Q4 Sales Growth In Low Teens; Says ‘operations and those of its suppliers are expected to be impacted by ongoing supply chain challenges and raw material shortages’

By Bill Haddad

April 6, 6:46 AM

Business Outlook For the fiscal 2022 fourth quarter, RPM's operations and those of its suppliers are expected to be impacted by ongoing supply chain challenges and raw material shortages, which will exert

RPM

Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics

By Vandana Singh

January 3, 1:03 PM

BTIG initiated coverage of Pear Therapeutics Inc (NASDAQ: PEAR) with a Buy rating and

PEAR

Kinnate Biopharma Q2 EPS $(0.62) Down From $(0.49) YoY

Related Posts

Apple App Store Settlement Reveals Updates: How Did A BofA Analyst React?

53 Biggest Movers From Yesterday

RPM Sees Q4 Sales Growth In Low Teens; Says ‘operations and those of its suppliers are expected to be impacted by ongoing supply chain challenges and raw material shortages’

Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics